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Abstract
It is controversial whether nitric oxide (NO) is protective or deleterious against ischemia^reperfusion injury. We examined
the effect of NO on PKC isoform translocation and protection against ischemia^reperfusion injury in perfused heart. An NO
synthase inhibitor L-NAME (NG-nitro-L-arginine methyl ester, 3.0 WM), administered only during reperfusion but not during
ischemia, inhibited the translocation of PKC-K, -N and -O isoforms to the nucleus^myofibril fraction and the translocation of
PKC-K to the membrane fraction after ischemia (20 min) and reperfusion (10 min) in the perfused rat heart. NO donors, 3-
morpholinosydnonimine (SIN-1) or S-nitroso-N-acetylpenicillamine (SNAP) activated purified PKC in vitro. SIN-1 also
induced PKC isoform translocation in perfused heart. On the other hand, PKC selective inhibitor, calphostin C (0.2 WM) or
chelerythrine (1.0 WM), aggravated the contractile dysfunction of ischemic heart during reperfusion, when they were perfused
during reperfusion. These data suggest that NO generated during reperfusion following ischemia activates PKC isoforms and
may protect the heart against contractile dysfunction in the perfused rat heart. ß 1999 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Nitric oxide (NO), formed by NO synthase (NOS),
relaxes vascular smooth muscle [1]. In the myocardi-
um, it is controversial whether NO exerts either pro-
tective or deleterious e¡ects against ischemia and re-
perfusion injury [2^6]. This may be because
ischemia^reperfusion generates both NO and O32
[7,8] ; during reperfusion, NO may neutralize the
harmful e¡ect of O32 , while the product of NO and
O32 , ONOO
3, may be cytotoxic through peroxida-
tion or tyrosine nitration [1,2,8]. In addition, the tim-
ing (preischemia or reperfusion) of administration of
NO donors or NOS inhibitors may cause the multi-
plicity of the e¡ects [2^6] of NO in the injury.
There are several studies concerning on the link
between NO or other reactive oxygens and intracel-
lular signaling pathways. For example, NO was
shown to mediate the activation of mitogen-activated
protein (MAP) kinase family in response to a NO
donor, or cytokines [9]. On the other hand, it was
shown that reactive oxygens modulate protein kinase
C (PKC) activation in vitro [10^12], and in cells
treated either with an anti-cancer reagent [13], ultra-
violet irradiation [14], or a herbicide paraquat [15].
Moreover, it was reported that NO generators mod-
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ulates PKC activity in vitro [16]. We have found that
ischemia^reperfusion induce the translocation or ac-
tivation of PKC isoforms [17], MAP kinase [18], and
cJun N-terminal kinase (JNK) [19] in perfused rat
heart. These studies led us to a hypothesis that
PKC or other intracellular signaling pathways may
be activated by NO or other reactive oxygen species
during ischemia^reperfusion.
PKC transduces extracellular signal to the mem-
brane, nucleus or other compartments through trans-
location [17,20^22]. There are Ca2, diacylglycerol-
dependent (conventional, c), Ca2-independent (nov-
el, n) PKC, and diacylglycerol-independent (atypical,
a) PKC isoforms [9,20^22]. We reported the di¡er-
ential translocation of cPKC-K, nPKC-N, -O, and
aPKC-j to the membrane or nucleus in ischemic
rat heart [17]. PKC regulates myocardial contractility
[21,22] and mediates the protective e¡ect of ischemic
preconditioning [23,24]. To the contrary, PKC was
shown to mediate deleterious e¡ects of NO in ische-
mic neuronal injury [25]. The increased association
(translocation) of a PKC isoform to a particular
fraction in a EGTA-resistant fashion after a stimulus
is a hallmark indicating that the PKC isoform is
activated by the stimulus and plays a role at the
intracellular compartment [10,17,21^24].
In the present study, we examined whether NO
mediates the activation of PKC isoforms and thereby
protects the perfused rat heart against ischemia^re-
perfusion injury. To this end, we examined the e¡ects
of a NOS inhibitor (L-NAME), perfused either dur-
ing preischemic period or reperfusion, on the trans-
location of PKC isoforms and on the contractile dys-
function after ischemia^reperfusion.
2. Materials and methods
2.1. Materials
Antibodies to PKC-K, -N, -j were obtained from
Transduction Laboratories (Lexington, KY), anti-
PKC-O from Gibco BRL (Gaitherburg, MD). Anti-
4-hydroxynonenal protein was a generous gift of Dr.
K. Uchida (Nagoya University School of Agricul-
ture). SIN-1 and SNAP were purchased from Dojin-
do Laboratories (Kumamoto, Japan), puri¢ed rat
brain PKC, calphostin C and chelerythrine from Cal-
biochem (La Jolla, CA), Pep Tag PKC assay kit
from Promega (Madison, WI), ECL Western blotting
detection kit from Amersham Life Science (Bucking-
hamshire, UK).
2.2. Perfusion procedure and protocols
The protocol was approved by the Committee of
the Ethics of Animal Experiments of Yamaguchi
University School of Medicine. Male Wistar rats
weighing 300^400 g were anesthetized with sodium
pentobarbital (1.0 mg/kg, i.p) and the hearts were
perfused with Krebs^Hensleit (KH) solution gassed
with 95% O2^5% CO2 at a constant pressure of 80
cm H2O for about 10 min and then subjected either
to ischemia for 20 min followed by 10 min of reper-
fusion at 37‡C (reperfusion (IR) group, n = 7) or to
control perfusion for 30 min (control, n = 7) as pre-
viously reported [26]. L-NAME (3.0 WM, n = 7) was
perfused 5 min before the onset of ischemia in the
preischemia group (no L-NAME during reperfusion).
In the reperfusion groups, we perfused either L-
NAME (3.0 WM, n = 5; 1.0 WM, n = 7; 0.3 WM,
n = 4), D-NAME (3.0 WM, n = 4), calphostin C (0.2
WM, n = 4), or chelerythrine (1.0 WM, n = 4) during 10
min of reperfusion. The left ventricular developed
pressure (LVDP) was monitored through a latex bal-
loon connected to a pressure transducer attached to
a Macintosh computer loaded with an analysis sys-
tem (MacLab, AD Instruments). The values (means
þ S.E.) of LVDP recovery and coronary £ow after
treatment or ischemia^reperfusion were expressed as
% of preischemic values of the same hearts after the
stabilizing perfusion. The basal value for LVDP be-
fore ischemia is 89.5+2.4 mmHg with diastolic pres-
sure adjusted at 10 mmHg. We chose the L-NAME
concentration of 3.0 WM that minimally reduced cor-
onary £ow (90.3 þ 4.1% of pretreatment value,
P6 0.05, n = 9) and LVDP (92.3 þ 5.1% of pretreat-
ment value) in non-ischemic heart, but was shown to
block the cyclic GMP generation during reperfusion
[27] and to inhibit negative inotropy by cytokines
[28]. The latter study also showed that 10 WM L-
NAME markedly reduces coronary £ow [28].
2.3. Subcellular fractionation
As previously reported [17^19], the frozen hearts
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were homogenized in bu¡er containing 0.32 M su-
crose, 10 mM Tris-HCl, pH 7.4, 1 mM EGTA, 5 mM
NaN3, 10 mM L-mercaptoethanol, 20 WM leupeptin,
0.15 WM pepstatin A, 0.2 mM phenylmethane-
sulfonyl £uoride and 50 mM NaF (STE bu¡er)
with a Polytron homogenizer at the maximum speed
(PT1200, Kinematica AG, Switzerland) three times
30 s each. The homogenates were centrifuged at
1000Ug for 10 min, and then the supernatant was
spun at 100 000Ug for 60 min. The 1000Ug pellet,
100 000Ug pellet and 100 000Ug supernatant were
referred to as the P1, P2 and S fractions, respectively.
Protein was determined by the method of Lowry [29].
2.4. Immunoblotting and quanti¢cation of PKC
isoforms
The fractions were subjected to SDS-polyacryla-
mide gel electrophoresis on 7.5% polyacrylamide
gels by the method of Laemmli [30] and then to
immunoblotting according to Towbin et al. [31]
with the modi¢cations as we previously described
[17^19]. The PKC isoforms were visualized using
an ECL Western blotting detection kit and the
amounts of PKC isoforms per ¢xed amount of pro-
tein (arbitrary unit; means þ S.E.; the means of the
control sample were expressed as 100) were measured
by an image analyzer (Densitograph AE-6900, Atto)
as we described in detail in previous papers [17^19].
2.5. E¡ect of NO donors on the PKC activity of
puri¢ed PKC in vitro
We used PKC that was puri¢ed from rat brain
(Calbiochem), the richest source of PKC. The PKC
contained PKC-K and -O but not PKC-N and -j (not
shown). The PKC (35 Wg, 270 U/mg protein) was
incubated either with various concentrations of
SIN-1 or SNAP at 25‡C in bu¡er containing 20
mM Tris-HCl, pH 7.4, 10 mM MgCl2, 1 mM dithio-
threitol, 1.5 mM CaCl2 and 20 Wg/ml of phospha-
tidylserine, 0.08 mg/ml of speci¢c £uorescent peptide
for PKC and the activity was measure by a Pep Tag
PKC assay kit [17].
2.6. Statistics
P6 0.05 is considered statistically signi¢cant by
the analysis using ANOVA with post-hoc analysis
of Fisher.
3. Results
3.1. E¡ect of L-NAME on PKC translocation after
ischemia^reperfusion
We examined the e¡ect of a NOS inhibitor, L-
NAME, on the translocation of PKC isoforms after
ischemia (20 min) followed by reperfusion (10 min).
The P1 and P2 fractions represent the nucleus^myo-
¢bril fraction and the membrane fraction, respec-
tively [17^19]. We chose the reperfusion time of 10
min because the translocation of PKC isoforms was
reversed after 30 min. During ischemia^reperfusion,
the total amount of each PKC isoform remained
unaltered [17,24], indicating that the change in the
association of each PKC isoform in the P1 or P2
fraction re£ects the PKC isoform translocation.
The e¡ects of L-NAME on the P1 translocation of
PKC isoforms are shown in a representative immu-
noblot (Fig. 1) and in the quanti¢cation of the blots
Fig. 1. Immunoblots showing the e¡ect of L-NAME on the
PKC translocation to the P1 and P2 fractions after ischemia^re-
perfusion. The control hearts (C) and the hearts subjected to is-
chemia (20 min)^reperfusion (10 min) (IR) or ischemia^reperfu-
sion with 3 WM L-NAME administered during either
preischemia (I) or reperfusion (R) were fractionated. The P1
(nucleus^myo¢bril) and P2 (membrane) fractions were subjected
to immunoblotting using anti-PKC-K, -N, -O and -j antibodies.
L-NAME, perfused during reperfusion, inhibited the transloca-
tion of PKC-K, -N, and -O, but not PKC-j translocation.
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(Fig. 2). In the absence of L-NAME, ischemia^reper-
fusion increased the amount of PKC-K, -N, -O and -j
signi¢cantly in the P1 fraction as compared with
control. L-NAME (3.0 WM), when it was perfused
during reperfusion, inhibited the translocation of
PKC-K, -N and -O, but not that of PKC-j. There
was no detectable signi¢cant inhibition of the PKC
translocation by the preischemic perfusion. The re-
duction of PKC translocation with 1.0 WM L-NAME
was not signi¢cant, and 0.3 WM L-NAME or 3.0 WM
D-NAME had no e¡ect (data not shown).
The e¡ects of L-NAME on the P2 translocation of
PKC isoforms are shown in representative immuno-
blots (Fig. 1) and in their quanti¢cation (Fig. 3). L-
NAME, perfused during reperfusion, also inhibited
the membrane (P2) translocation of PKC-K induced
by ischemia^reperfusion. PKC-N was dissociated
from the P2 fraction after the reperfusion, but there
was neither di¡erence in the P2 level of PKC-O and -j
after the reperfusion nor the e¡ect of L-NAME on
the level of PKC-N, -O and -j.
3.2. E¡ect of L-NAME on myocardial contractile
dysfunction during reperfusion
We then examined the e¡ect of L-NAME (3.0 WM)
on the left ventricular contractility during ischemia^
reperfusion under the same conditions for the PKC
translocation analysis. Fig. 4 shows that L-NAME
itself did not a¡ect LVDP in non-ischemic heart
and the functional recovery assessed by the LVDP
after 10 min of reperfusion following 20 min of is-
chemia (control) was about 30% of preischemia level.
The LVDP recovery worsened when L-NAME was
given during reperfusion, but not in preischemic pe-
riod. PKC selective inhibitor, calphostin C (0.2 WM)
Fig. 2. E¡ects of L-NAME on P1 translocation of PKC isoforms after ischemia^reperfusion. The P1 fractions from control hearts and
hearts after ischemia (20 min)^reperfusion (10 min) in the absence or in the presence of L-NAME either during preischemia or reper-
fusion were subjected to immunoblotting as shown in Fig. 1. The amounts of PKC-K, -N, -O and -j in the P1 fraction (mean þ S.E.,
expressed as arbitrary units) were quanti¢ed from the immunoblots. PKC-K, -N, -O and -j were increased after ischemia^reperfusion in
the absence of L-NAME (C), while the reperfusion-induced translocation of PKC-K, -N and -O was inhibited by L-NAME when it was
given only during reperfusion (Rep) but not during preischemic period (Pre-I). *P6 0.05.
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or chelerythrine (1.0 WM), given during reperfusion,
also reduced the LVDP recovery. Since L-NAME
administration, administered only during reperfu-
sion, decreased both the PKC translocation (Figs.
1^3) and functional recovery after ischemia^reperfu-
sion (Fig. 4) in a similar fashion, NO may be in-
volved in the restitution of contractile dysfunction
in the reperfused heart via PKC-dependent mecha-
nisms. The e¡ect of L-NAME is not secondary to its
e¡ects on coronary £ow after the reperfusion (L-
NAME, 60.2 þ 12.5%; no L-NAME, 70.7 þ 4.9% of
preischemic value) or the heart rate.
3.3. Translocation in perfused heart and in vitro
activation of PKC by NO donors
Fig. 5 shows that a NO donor, SIN-1 induced the
translocation of PKC isoforms to the P1 and P2
fraction in perfused heart in a similar fashion to
that following ischemia^reperfusion. However, an-
other NO donor SNAP did not signi¢cantly induced
the PKC isoform translocation (data not shown). As
shown in Fig. 6, although the two NO donors sig-
ni¢cantly activated the PKC activity of puri¢ed PKC
in vitro (P6 0.05 vs. control), the maximum activa-
tion with 1 WM SIN-1 (183.3 þ 25.0% of control) was
greater than that with 1 WM SNAP (154.4 þ 6.9% of
control). The in vitro PKC activation peaked at 1 WM
with decline with higher concentrations of the NO
donors (Fig. 6). An anti-oxidant N-acetylcysteine
did not a¡ect the PKC activation induced by the
two NO donors (data not shown).
To further investigate if the PKC activation after
ischemia^reperfusion is due to the oxidation or tyro-
sine-nitration of PKC molecule, we examined these
modi¢cations of PKC by immunoblotting using anti-
4-hydroxy-2-nonenal (HNE) antibody [32] or anti-
nitrotyrosine antibody. We did not detect such mod-
Fig. 3. E¡ects of L-NAME on P2 translocation of PKC isoforms after ischemia^reperfusion. The P2 fractions from control heart and
hearts after ischemia (20 min)^reperfusion (10 min) in the absence (C) or presence of L-NAME, given either during preischemia (Pre-
I) or reperfusion (Rep) were immunoblotted as shown in Fig. 1. The amounts of PKC-K, -N, -O and -j in the P2 (mean þ S.E., ex-
pressed as arbitrary units) were quanti¢ed from the immunoblots. PKC-K increased after ischemia^reperfusion, while L-NAME inhib-
ited the translocation when it was perfused during reperfusion, but not during ischemia. *P6 0.05.
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i¢cations of the bands with the same electrophoretic
mobility with PKC isoforms (data not shown).
4. Discussion
This study provides the ¢rst line of evidence for
the involvement of NO in the PKC isoform trans-
location and restitution of the contractile dysfunction
in the reperfused heart following ischemia. This con-
clusion was veri¢ed by the observations that an NOS
inhibitor reduced the PKC isoform translocation and
functional recovery during reperfusion following is-
chemia. The NO-dependent activation of PKC was
supported by in vitro activation of puri¢ed PKC by
SIN-1 or SNAP with a maximum activation at 1 WM,
with decline at higher concentrations. Our observa-
tions would not be contradictory to the previous re-
port on a reversible inactivation of PKC phospho-
transferase and phorbol ester binding activities in
vitro and in cultured cells by NO generating agents
with much higher concentrations [16,17,20^22],
which may inactivate or down-regulate PKC.
4.1. How does L-NAME inhibit PKC isoform
translocation?
Ischemia (20 min)^reperfusion (10 min)-induced
translocation of PKC-K, -N, -O and -j to the nu-
cleus^myo¢bril (P1) fraction and PKC-K to the
membrane (P2) fraction (Figs. 1^3). L-NAME, at
the concentration (3.0 WM) that minimally reduces
coronary £ow, inhibited the translocation of PKC-
K, -N and -O to the P1 fraction and that of PKC-K to
the P2 fraction after ischemia^reperfusion. Our ob-
servation is consistent with the ¢nding of Zablocka
et al. that L-NAME inhibits the translocation of
phorbol ester binding activity in ischemic brain [25].
In the previous studies, the direct measurement of
NO in the ischemic heart using electron paramag-
netic resonance spectroscopy showed that NO gener-
ation increases to a small extent at 20 min of ische-
mia in perfused rat heart [7], but that NO and
ONOO3 increases rapidly and greatly in the early
phase of reperfusion following ischemia and the in-
crease is blocked by L-NAME [8]. These observations
are consistent with our observation that L-NAME
Fig. 4. E¡ects of L-NAME or PKC inhibitors on left ventricular developed pressure (LVDP, expressed as % of preischemic value,
means þ S.E.) at 10 min of reperfusion after 20 min of ischemia. The L-NAME perfusion did not a¡ect LVDP in non-ischemic heart.
The LVDP recovery after postischemic reperfusion was exacerbated by either L-NAME (3.0 WM; Rep.), calphostin C (0.2 WM; Calp.),
or chelerythrine (1.0 WM; Cele.), when they were perfused during reperfusion, as compared with ischemia^reperfusion with no L-
NAME (No). L-NAME given during preischemia (Pre-Is.) had no e¡ect. *P6 0.05.
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inhibited PKC-K, -N and -O translocation when it was
administered during reperfusion, but not in preische-
mic period (Figs. 1^3). SIN-1 (a donor of NO and
O32 that generates ONOO
3) but not SNAP (a NO
donor) induced PKC isoform translocation in per-
fused heart to a similar fashion to that after ische-
mia^reperfusion (Fig. 5) may be explained by assum-
ing that ONOO3, but not NO induced detectable
translocation of PKC isoforms in perfused heart. Al-
ternatively, it may be due either to the lower extent
of PKC activation by SNAP (154%) than that by
SIN-1 (183%) as shown in in vitro activation or pos-
sibly lower permeability of SNAP than SIN-1 to the
heart membrane. On the other hand, because reper-
fusion greatly increases intracellular Ca2 concentra-
tion [33], the burst-like formation of NO and
ONOO3 as reported to be induced during reperfu-
sion [8], may be derived from Ca2-activated constit-
utive NOS in the endothelial cells and cardiomyo-
cytes [1]. The latter explains why L-NAME was
e¡ective only when it was administered during reper-
fusion.
4.2. Physiological implication and mechanism of PKC
isoform translocation
It is believed that PKC mediates the protective
e¡ects conferred by the ischemic preconditioning
most likely through the phosphorylation of mem-
brane proteins, such as 5P-nucleotidase [23,24]. In
support of the protective role of PKC, this study
showed that L-NAME inhibited both PKC translo-
cation and LVDP recovery after ischemia^reperfu-
Fig. 6. Activation of PKC by NO donors in vitro. The puri¢ed PKC was incubated with various concentrations of SIN-1 or SNAP
and the activity was measured as described in Section 2. *P6 0.05 vs. zero NO donors.
Fig. 5. E¡ect of SIN-1 on PKC translocation in perfused heart.
The heart was perfused with either 0, 5, or 50 WM of SIN-1 at
37‡C for 10 min. A representative blot (equal amount of the P1
or P2 fraction was immunoblotted) of three similar experiments
are shown. For details, see text.
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sion and PKC selective inhibitors suppressed the
LVDP recovery (Figs. 1^4). In addition, we also
found that PKC translocation and functional recov-
ery was both inhibited when L-NAME was adminis-
tered during reperfusion, but not in preischemic pe-
riod (Figs. 1^4). As to the controversy whether NO is
protective or deleterious against ischemia^reperfu-
sion injury [2^6], we think that NO is protective dur-
ing the early phase of postischemic reperfusion, but
the NOS inhibitor is ine¡ective when it is given dur-
ing ischemia.
The cardiac contractility is regulated at the levels
of contractile proteins (e.g. troponin) and intracellu-
lar Ca2 regulation (e.g. Ca2 channels, Na/H ex-
changers, and Na/Ca2 exchangers) [21,22]. The
NO-mediated PKC translocation to the myo¢bril-nu-
cleus or the membrane fraction may modulate these
processes through phosphorylation. In support of the
latter idea, it was shown that NO a¡ects contractility
[35], intracellular Ca2 regulation [36], mitochondrial
respiration [34], glycolysis [37] and membrane per-
oxidation [1,2,8]. These e¡ects of NO may be also
mediated by PKC.
Although we found that PKC is activated directly
by NO donors, the mechanism of activation of PKC
isoforms by NO remains to be elucidated. It is
known that NO induces S-nitrosylation of cysteine
residues, scavenges tyrosyl residues, and deaminates
primary amine residues in proteins [9,13]. However,
we could neither detect oxidation (HNE modi¢ca-
tion) nor tyrosine nitration of PKC under the present
experimental conditions. Additionally, an antioxi-
dant, N-acetylcysteine hardly a¡ected the NO do-
nor-induced PKC activation of puri¢ed PKC, sug-
gesting that modi¢cation of the sulfhydryl group
may not be a main cause of NO-induced activation
of PKC isoforms.
In conclusion, we found that NO contributes to
PKC isoform translocation and protection against
contractile dysfunction during postischemic reperfu-
sion in perfused heart at least partly through direct
activation of PKC molecule.
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